Abstracts

ANTIGENICITY OF THE MU (B.1.621) AND A.2.5 SARS-CoV-2 SPIKES

The rapid emergence of SARS-CoV-2 variants is fueling the recent waves of the COVID-19 pandemic. Recently identified Mu (B.1.621) and A.2.5 variants carry some mutations shared by other variants of concerns (VOCs). For example, N501Y and E484K mutations in the receptor-binding domain (RBD) domain detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now…

UPREGULATION OF INTERFERON-STIMULATED GENES PERSISTS DURING TREATED HIV-1 INFECTION

Despite the capacity of antiretroviral therapy (ART) to suppress HIV-1, ART-treated persons living with HIV-1 and undetectable plasma HIV-1 have higher comorbidity rates than people without HIV-1, potentially due in part to chronic immune activation that persists during treatment. We previously found that certain interferon-stimulated genes (ISGs) are persistently upregulated during untreated infection and may…

INFLAMMATION AND IMMUNE ACTIVATION NOT DRIVEN BY ON-ART HIV-SPECIFIC IMMUNE RESPONSES

People living with HIV (PLWH) have persistently elevated levels of inflammation and immune activation despite suppressive antiretroviral therapy (ART). Because adaptive immune responses against HIV persist in PLWH on ART, and show evidence of ongoing antigenic stimulation, we hypothesized that they contribute to this phenomenon. We therefore investigated potential associations between HIV-specific T-cell and antibody…

RECTAL TISSUE HIV RNA IS ASSOCIATED WITH SYSTEMIC INFLAMMATION IN PERSONS WITH HIV

Non-AIDS comorbidities account for significant morbidity/mortality in persons with HIV (PWH). The gastrointestinal tract contributes to systemic immune dysfunction. We assessed associations between detectable rectal tissue (RT) HIV-RNA with 1) systemic inflammatory and hypercoagulation biomarkers and 2) presence of replication-competent virus. Treatment-naïve PWH initiating dolutegravir-based antiretroviral therapy (ART) underwent blood and RT sampling pre-ART (wk…

STRUCTURAL CHARACTERIZATION OF DNA-ENCODED HIV VACCINES INDUCED NEUTRALIZING ANTIBODY

Rapid and large-scale deployment of COVID-19 mRNA vaccines highlights the potential utility of developing nucleic acid vaccines (such as RNA and DNA vaccines) against infectious diseases, including HIV-1. However, as compared to SARS-CoV-2, HIV-1 pose some unique challenges- induction of neutralizing antibodies (NAbs) against HIV-1 (frequently a correlate of protection) requires presentation of trimeric and…

HIV VACCINE CANDIDATE EFFICACY MEDIATED BY CAMP-DEPENDENT EFFEROCYTOSIS AND V2-ADCC

The DNA/ALVAC-SIV/gp120 vaccine significantly decreased the risk of SIVmac251 rectal acquisition. The levels of CD14+ monocytes and the Antibody-dependent cellular cytotoxicity (ADCC) to the V2 of SIV were correlated with reduced risk of acquisition, indicating the central role of innate response in mounting an effective response to vaccination. In-depth understanding of the innate and adaptive…